Holen Sie sich die Stockscreener-App
101.66
0.97%
0.98
Handel nachbörslich:
101.30
-0.36
-0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$100.68
Offen:
$100.7
24-Stunden-Volumen:
14.37M
Relative Volume:
1.06
Marktkapitalisierung:
$177.07B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
32.86
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
+10.37%
1M Leistung:
+14.99%
6M Leistung:
-16.08%
1J Leistung:
-17.80%
1-Tages-Spanne:
$100.03
$102.46
1-Wochen-Bereich:
$87.64
$102.46
52-Wochen-Spanne:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
101.66 | 175.37B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
319.14 | 122.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.29 | 106.50B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.77 | 65.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.00 | 49.36B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Craneware, Abbott Probe Separate Health Data Theft Incidents - BankInfoSecurity
Abbott Laboratories (NYSE:ABT) Faces A Major Medical Device Growth Test - Kalkine Media
ShinyHunters hit medial giant Abbott, disrupting cancer drug research and more - Yahoo Tech
Abbott Investigating Cyberattack Claims From Two Threat Actors - The HIPAA Journal
Healthcare giant Abbott probes two cyber incidents amid extortion claims - Malwarebytes
Abbott Laboratories investigates 2 separate cyber incidents - SC Media
Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - LinkedIn
Benchmark reiterates Buy on Abbott Labs stock, cites guidance raise - Investing.com
Abbott Laboratories stock trades steady as diagnostics and medical devices support growth - Ad-hoc-news.de
Cybersecurity News: Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - CISO Series
Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident - Rescana
Abbott Investigates Two Separate Cyber Incidents, Says No Operations Affected - Insurance Journal
Abbott Laboratories stock holds firm as diagnostics and medical devices support earnings - ad-hoc-news.de
Medical giant Abbott investigates two cyber incidents as ShinyHunters claims breach - Cybernews
This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year - The Motley Fool
Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative - simplywall.st
Abbott Stock: Bear Trap Over, With Richer Return Prospects (NYSE:ABT) - Seeking Alpha
Abbott Just Showed Its Growth Engine Has More Than One Cylinder - Trefis
Abbott investigates two separate cyber incidents, says no operations affected By Reuters - Investing.com
Abbott investigates two cyber intrusions targeting cancer diagnostics and LabCentral portal - Межа. Новини України.
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Keysight Invalidates IRS Rule On GILTI, Abbott Says - Law360
US companies face rise in cyber attacks - Reuters
Bernstein Adjusts Price Target on Abbott Laboratories to $117 From $110, Maintains Outperform Rating - Moomoo
Abbott probes two cyber incidents amid extortion claims - BleepingComputer
Abbott discloses cyberattack on cancer diagnostics business - MedTech Dive
ABT Reiterated by Piper Sandler -- Price Target Raised to $118 - GuruFocus
Can Abbott Laboratories (NYSE:ABT) Extend Its Dividend Strength? - Kalkine Media
Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance - TIKR.com
Abbott Laboratories Stock (ABT) Moved Up by 3.03% on Jul 17: Drivers Behind the Movement - TradingKey
ABT Q2 Earnings Call Flags Stronger Second-Half Setup - The Globe and Mail
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results - Benzinga
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target - Investing.com
Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight Rating - Moomoo
Can Abbott Stock Deliver on Its Second-Half Growth Promise? - Trefis
Abbott Laboratories stock could rise 40%+ by 20... - Pluang
JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform Rating - marketscreener.com
Abbott Laboratories: Pick Up This Dividend King Deal Now - Seeking Alpha
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - The Motley Fool
Abbott Laboratories Earnings Call Signals Broad-Based Momentum - TipRanks
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Abbott Is On Deck to Launch Several New Devices - Morningstar
ABT: Abbott Laboratories Exceeds Expectations and Raises Profit Outlook - GuruFocus
Abbott Laboratories’s Stock Price Soars to $98.83, Enjoying a Robust 10.71% Uptick - Smartkarma
BTIG raises Abbott Labs stock price target to $134 on Q2 strength - Investing.com
Strong Demand and Growth Forecast for Abbott Laboratories (ABT) - GuruFocus
Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Stro - GuruFocus
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):